These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36757299)

  • 1. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
    Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
    Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
    Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
    Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
    Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
    Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
    Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
    Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.